Table 1. Demographic characteristics of patients with positive isolates for imipenem-resistant Acinetobacter baumannii (IRAB).
| Variable | No of patients (%) n = 40 |
| Age (years), mean ± SD | 69.2±16.3 |
| Male (%) | 24 (60.0) |
| Underlying disease | |
| Diabetes mellitus | 14 (35.0) |
| Cancer | 13 (32.5) |
| Stroke | 7 (17.5) |
| Chronic kidney disease | 5 (12.5) |
| Liver cirrhosis | 4 (10.0) |
| Connective tissue disease | 2 (5.0) |
| Use of steroid | 6 (15.0) |
| Use of immunosuppressant | 4 (10.0) |
| Site of isolates | |
| Endotracheal aspirate | 30 (75.0) |
| Catheter tip | 4 (10.0) |
| Blood | 3 (15.0) |
| Urine | 2 (5.0) |
| Wound | 2 (5.0) |
| Device | |
| Endotracheal tube | 37 (92.5) |
| Central venous catheter | 32 (80.0) |
| Port-A catheter | 7 (17.5) |
| Double lumen catheter | 4 (10.0) |
| AV shunt | 1 (2.5) |
| Abdominal drainage | 4 (10.0) |
| Pleural drainage | 2 (5.0) |
| Total parenteral nutrition | 3 (7.5) |
| Previous use of antibiotic in the preceding 90 days | |
| Fluoroquinolones | 27 (67.5) |
| Carbapenem | 17 (42.5) |
| Extended-spectrum cephalosporin | 16 (40.0) |
| Extended-spectrum β-lactam-β-lactamase inhibitor combinations | 7 (17.5) |
| Hospital stay before acquisition of IRAB (days) | 14.4±9.4 |
| ICU stay before acquisition of IRAB (days) | 10.1±5.5 |
| Clinical significance | |
| Colonization | 22 (55.0) |
| Ventilator associated pneumonia | 15 (30.0) |
| Central venous catheter related infection | 2 (10.0) |
| Skin and soft tissue infection | 1 (5.0) |
| Outcome | |
| In-hospital mortality | 10 (25.0) |